This Stock Just Jumped By 8%: Is It Too Late to Buy?

Vertex Pharmaceuticals (NASDAQ: VRTX) has encountered several clinical setbacks over the past 18 months, including for two products in its growing pain medicine franchise. Even with recent approvals outside its core therapeutic area of drugs that treat the underlying causes of cystic fibrosis (CF), given the slow commercial uptake of these newer products and recent clinical trial failures, some investors were starting to doubt the company's ability to perform well outside its CF business. However, the bio ...